Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc.
Your view on DNTH
Overview
What the company does, where it operates, and who runs it.
About Dianthus Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Marino Garcia
- Headquarters
- 7 Times Square, New York City, NY, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Marino Garcia
- Headquarters
- 7 Times Square, New York City, NY, US
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Infographics
Visual summary of the business at a glance.
Media
Videos and interviews covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Comparables
List of peer companies in the same industry.
Institutional Ownership
Which funds and firms own the stock.
Insider Trading
Recent buying and selling by company executives.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
News
Latest headlines and market coverage.